Boston Scientific patents closed‑loop DBS

Boston Scientific added three U.S. patents on September 1 that show how it is trying to make deep-brain stimulation systems more responsive to signals coming back from the brain. The patents cover the use of evoked potentials in DBS, an algorithm for adjusting compliance voltage in a stimulator with neural sensing capability, and closed-loop DBS programming based on evoked signals and local field potential signals. (patentsgazette.uspto.gov) The grants were published in the U.S. Patent and Trademark Office’s weekly patent gazette. The filings matter because they document where one of the established DBS manufacturers is spending intellectual-property effort: not just delivering current, but sensing neural activity, interpreting it and using it to adjust therapy. Separate patents issued the same day to university-backed teams point in a similar direction, including cortical sensory feedback and restoration of brain-network activity. (bostonscientific.com) ### What did Boston Scientific’s new patents actually cover? U.S. Patent 12,721,685, titled “Use of evoked potentials in deep brain stimulation neuromodulation,” describes methods in which stimulation is delivered and evoked potentials are recorded at multiple electrodes to help estimate whether electrodes are in the same or different anatomical regions and to support DBS delivery decisions. (patentsgazette.uspto.gov) U.S. Patent 12,722,011, titled “Algorithm for adjusting a compliance voltage in a stimulator device having neural sensing capability,” covers ways to monitor and adjust compliance voltage in an implantable stimulator that also senses neural signals. In implantable stimulators, compliance voltage is part of the electrical headroom needed to deliver programmed pulses. (patentsgazette.uspto.gov) U.S. Patent 12,722,012, titled “Closed-loop deep brain stimulation programming based on evoked signals and local field potential signals,” describes a system that stores stimulation parameters, measures evoked and local field potential signals, and uses those signals in therapy programming. ### Why do evoked potentials and local field potentials matter in DBS? Closed-loop brain stimulation uses a readout from the brain to adjust later stimulation, rather than relying only on fixed settings, according to a 2024 review in *Biological Psychiatry*. (patentsgazette.uspto.gov) Local field potentials, or LFPs, are electrical signals recorded from implanted electrodes that can reflect ongoing neural activity. A 2025 review in *Brain Sciences* said newer DBS systems can record LFPs and that the signals may help streamline programming, though clinically useful biomarkers remain an active area of work. (patentsgazette.uspto.gov) ### How does this fit Boston Scientific’s current device lineup? Boston Scientific already markets the Vercise Genus DBS system, which the company says offers multiple implantable pulse generator options and tools for personalized therapy programming. (patentsgazette.uspto.gov) The company’s product materials describe the system as part of its DBS platform for movement disorders including Parkinson’s disease, dystonia and essential tremor. (sciencedirect.com) The new patents do not by themselves show that these specific closed-loop features are commercially available. Patents protect claimed inventions, but they are not product clearances, reimbursement decisions or treatment guidelines. ### Which other September 1 patents point in the same direction? U.S. Patent 12,722,013 names the University of Washington and covers a “system and method for delivering sensory feedback to the cortex via electrical stimulation.” The patent describes cortical stimulation for sensory feedback rather than DBS for movement disorders, but it also centers on bidirectional neurotechnology. (mdpi.com) U.S. Patent 12,722,008, assigned to EPFL, Cornell University and the University of Minnesota, covers “methods and apparatus for restoration of brain network activity.” The published application says the disclosure concerns closed-loop, on-demand implantable neuromodulation to control connectivity between brain regions. (bostonscientific.com) ### What should readers watch next? September 1 is the key date for these U.S. grants, but the more consequential milestones will be later ones: product documentation, regulatory submissions, clinical-study disclosures and additional patent grants tied to the same families. (uspto.gov) Boston Scientific’s healthcare professional materials for Vercise Genus and the USPTO’s public patent databases are the main places to track that follow-through. (bostonscientific.com) (patents.justia.com) (patentsgazette.uspto.gov)